Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Therapeutic Delivery of miR-148a Suppresses Ventricular Dilation in Heart Failure.

Raso A, Dirkx E, Philippen LE, Fernandez-Celis A, De Majo F, Sampaio-Pinto V, Sansonetti M, Juni R, El Azzouzi H, Calore M, Bitsch N, Olieslagers S, Oerlemans MIFJ, Huibers MM, de Weger RA, Reckman YJ, Pinto YM, Zentilin L, Zacchigna S, Giacca M, da Costa Martins PA, López-Andrés N, De Windt LJ.

Mol Ther. 2019 Mar 6;27(3):584-599. doi: 10.1016/j.ymthe.2018.11.011. Epub 2018 Nov 17.

2.

Comparison of different chemically modified inhibitors of miR-199b in vivo.

Duygu B, Juni R, Ottaviani L, Bitsch N, Wit JBM, de Windt LJ, da Costa Martins PA.

Biochem Pharmacol. 2019 Jan;159:106-115. doi: 10.1016/j.bcp.2018.11.013. Epub 2018 Nov 16.

3.

Non-coding RNA function in stem cells and Regenerative Medicine.

De Windt LJ, Giacca M.

Noncoding RNA Res. 2018 Apr 20;3(2):39-41. doi: 10.1016/j.ncrna.2018.04.004. eCollection 2018 Jun. No abstract available.

4.

RNA therapeutics for heart disease.

De Majo F, De Windt LJ.

Biochem Pharmacol. 2018 Sep;155:468-478. doi: 10.1016/j.bcp.2018.07.037. Epub 2018 Jul 29. Review.

PMID:
30059676
5.

If you like it, put a ring on it!

El Azzouzi H, De Windt LJ.

Cardiovasc Res. 2018 Oct 1;114(12):1575-1577. doi: 10.1093/cvr/cvy190. No abstract available.

PMID:
30052806
6.

The MEF2 transcriptional target DMPK induces loss of sarcomere structure and cardiomyopathy.

Damanafshan A, Elzenaar I, Samson-Couterie B, van der Made I, Bourajjaj M, van den Hoogenhof MM, van Veen HA, Picavet DI, Beqqali A, Ehler E, De Windt LJ, Pinto YM, van Oort RJ.

Cardiovasc Res. 2018 Sep 1;114(11):1474-1486. doi: 10.1093/cvr/cvy091.

PMID:
29648621
7.

The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC.

Frantz S, Falcao-Pires I, Balligand JL, Bauersachs J, Brutsaert D, Ciccarelli M, Dawson D, de Windt LJ, Giacca M, Hamdani N, Hilfiker-Kleiner D, Hirsch E, Leite-Moreira A, Mayr M, Thum T, Tocchetti CG, van der Velden J, Varricchi G, Heymans S.

Eur J Heart Fail. 2018 Mar;20(3):445-459. doi: 10.1002/ejhf.1138. Epub 2018 Jan 15. Review.

8.

MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload-Induced Heart Failure.

Verjans R, Peters T, Beaumont FJ, van Leeuwen R, van Herwaarden T, Verhesen W, Munts C, Bijnen M, Henkens M, Diez J, de Windt LJ, van Nieuwenhoven FA, van Bilsen M, Goumans MJ, Heymans S, González A, Schroen B.

Hypertension. 2018 Feb;71(2):280-288. doi: 10.1161/HYPERTENSIONAHA.117.10094. Epub 2017 Dec 18.

PMID:
29255073
9.

An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology.

Lourenço AP, Leite-Moreira AF, Balligand JL, Bauersachs J, Dawson D, de Boer RA, de Windt LJ, Falcão-Pires I, Fontes-Carvalho R, Franz S, Giacca M, Hilfiker-Kleiner D, Hirsch E, Maack C, Mayr M, Pieske B, Thum T, Tocchetti CG, Brutsaert DL, Heymans S.

Eur J Heart Fail. 2018 Feb;20(2):216-227. doi: 10.1002/ejhf.1059. Epub 2017 Nov 16. Review.

10.

An unbiased silencing screen in muscle cells identifies miR-320a, miR-150, miR-196b, and miR-34c as regulators of skeletal muscle mitochondrial metabolism.

Dahlmans D, Houzelle A, Andreux P, Jörgensen JA, Wang X, de Windt LJ, Schrauwen P, Auwerx J, Hoeks J.

Mol Metab. 2017 Nov;6(11):1429-1442. doi: 10.1016/j.molmet.2017.08.007. Epub 2017 Aug 31.

11.

Wnt/β-catenin pathway in arrhythmogenic cardiomyopathy.

Lorenzon A, Calore M, Poloni G, De Windt LJ, Braghetta P, Rampazzo A.

Oncotarget. 2017 Apr 27;8(36):60640-60655. doi: 10.18632/oncotarget.17457. eCollection 2017 Sep 1. Review.

12.

Translational Perspective on Epigenetics in Cardiovascular Disease.

van der Harst P, de Windt LJ, Chambers JC.

J Am Coll Cardiol. 2017 Aug 1;70(5):590-606. doi: 10.1016/j.jacc.2017.05.067. Review.

13.

Why publish in the American Journal of Physiology-Heart and Circulatory Physiology?

Zucker IH, Lindsey ML, Delmar M, De Windt LJ, Des Rosiers C, Diz DI, Hester RL, Jones SP, Kanagy NL, Kitakaze M, Liao R, Lopaschuk GD, Patel KP, Recchia FA, Sadoshima J, Shah AM, Ungvari Z, Benjamin IJ, Blaustein MP, Charkoudian N, Efimov IR, Gutterman D, Kass DA, Liao Y, O'Leary DS, Ripplinger CM, Wolin MS.

Am J Physiol Heart Circ Physiol. 2017 Aug 1;313(2):H221-H223. doi: 10.1152/ajpheart.00329.2017. Epub 2017 Jun 16. No abstract available.

14.

Cardiac remodeling and pre-eclampsia: an overview of microRNA expression patterns.

Mohseni Z, Spaanderman MEA, Oben J, Calore M, Derksen E, Al-Nasiry S, de Windt LJ, Ghossein-Doha C.

Ultrasound Obstet Gynecol. 2018 Sep;52(3):310-317. doi: 10.1002/uog.17516. Review.

PMID:
28466998
15.

miR-199b-5p is a regulator of left ventricular remodeling following myocardial infarction.

Duygu B, Poels EM, Juni R, Bitsch N, Ottaviani L, Olieslagers S, de Windt LJ, da Costa Martins PA.

Noncoding RNA Res. 2017 Jan 13;2(1):18-26. doi: 10.1016/j.ncrna.2016.12.002. eCollection 2017 Mar.

16.

Pre-eclampsia: an important risk factor for asymptomatic heart failure.

Ghossein-Doha C, van Neer J, Wissink B, Breetveld NM, de Windt LJ, van Dijk AP, van der Vlugt MJ, Janssen MC, Heidema WM, Scholten RR, Spaanderman ME.

Ultrasound Obstet Gynecol. 2017 Jan;49(1):143-149. doi: 10.1002/uog.17343.

17.

Preclinical Development of a MicroRNA-Based Therapy for Elderly Patients With Myocardial Infarction.

Gupta SK, Foinquinos A, Thum S, Remke J, Zimmer K, Bauters C, de Groote P, Boon RA, de Windt LJ, Preissl S, Hein L, Batkai S, Pinet F, Thum T.

J Am Coll Cardiol. 2016 Oct 4;68(14):1557-71. doi: 10.1016/j.jacc.2016.07.739.

18.

Exosomes: scytales in the damaged heart.

Ottaviani L, De Windt LJ, da Costa Martins PA.

Ann Transl Med. 2016 Jun;4(11):222. doi: 10.21037/atm.2016.05.17. No abstract available.

19.

Long Non-Coding RNA Malat-1 Is Dispensable during Pressure Overload-Induced Cardiac Remodeling and Failure in Mice.

Peters T, Hermans-Beijnsberger S, Beqqali A, Bitsch N, Nakagawa S, Prasanth KV, de Windt LJ, van Oort RJ, Heymans S, Schroen B.

PLoS One. 2016 Feb 26;11(2):e0150236. doi: 10.1371/journal.pone.0150236. eCollection 2016.

20.

Long noncoding RNA Chast promotes cardiac remodeling.

Viereck J, Kumarswamy R, Foinquinos A, Xiao K, Avramopoulos P, Kunz M, Dittrich M, Maetzig T, Zimmer K, Remke J, Just A, Fendrich J, Scherf K, Bolesani E, Schambach A, Weidemann F, Zweigerdt R, de Windt LJ, Engelhardt S, Dandekar T, Batkai S, Thum T.

Sci Transl Med. 2016 Feb 17;8(326):326ra22. doi: 10.1126/scitranslmed.aaf1475.

PMID:
26888430
21.

MicroRNAs in heart failure: from biomarker to target for therapy.

Vegter EL, van der Meer P, de Windt LJ, Pinto YM, Voors AA.

Eur J Heart Fail. 2016 May;18(5):457-68. doi: 10.1002/ejhf.495. Epub 2016 Feb 11. Review.

22.

State-of-the-art on non-coding RNA bioinformatics, diagnostics and therapeutics in cardiovascular diseases: Preface to SI Non-coding RNAs in cardiovascular disease.

De Windt LJ, Thum T.

J Mol Cell Cardiol. 2015 Dec;89(Pt A):1-2. doi: 10.1016/j.yjmcc.2015.11.021. No abstract available.

PMID:
26694941
23.

Genetics meets epigenetics: Genetic variants that modulate noncoding RNA in cardiovascular diseases.

Calore M, De Windt LJ, Rampazzo A.

J Mol Cell Cardiol. 2015 Dec;89(Pt A):27-34. doi: 10.1016/j.yjmcc.2015.10.028. Epub 2015 Nov 9. Review.

PMID:
26546166
24.

Longing for Naiades in Heart Failure.

Calore M, De Windt LJ.

J Am Coll Cardiol. 2015 Nov 3;66(18):2016-2018. doi: 10.1016/j.jacc.2015.08.868. No abstract available.

25.

A novel miR-371a-5p-mediated pathway, leading to BAG3 upregulation in cardiomyocytes in response to epinephrine, is lost in Takotsubo cardiomyopathy.

d'Avenia M, Citro R, De Marco M, Veronese A, Rosati A, Visone R, Leptidis S, Philippen L, Vitale G, Cavallo A, Silverio A, Prota C, Gravina P, De Cola A, Carletti E, Coppola G, Gallo S, Provenza G, Bossone E, Piscione F, Hahne M, De Windt LJ, Turco MC, De Laurenzi V.

Cell Death Dis. 2015 Oct 29;6:e1948. doi: 10.1038/cddis.2015.280.

26.

Antisense MicroRNA Therapeutics in Cardiovascular Disease: Quo Vadis?

Philippen LE, Dirkx E, Wit JB, Burggraaf K, de Windt LJ, da Costa Martins PA.

Mol Ther. 2015 Dec;23(12):1810-8. doi: 10.1038/mt.2015.133. Epub 2015 Jul 28. Review.

27.

HypoxamiRs: regulators of cardiac hypoxia and energy metabolism.

Azzouzi HE, Leptidis S, Doevendans PA, De Windt LJ.

Trends Endocrinol Metab. 2015 Sep;26(9):502-8. doi: 10.1016/j.tem.2015.06.008. Epub 2015 Jul 18. Review.

PMID:
26197955
28.

Cardiac LXRα protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization.

Cannon MV, Silljé HH, Sijbesma JW, Vreeswijk-Baudoin I, Ciapaite J, van der Sluis B, van Deursen J, Silva GJ, de Windt LJ, Gustafsson JÅ, van der Harst P, van Gilst WH, de Boer RA.

EMBO Mol Med. 2015 Sep;7(9):1229-43. doi: 10.15252/emmm.201404669.

29.

Targeting microRNAs in heart failure.

Duygu B, de Windt LJ, da Costa Martins PA.

Trends Cardiovasc Med. 2016 Feb;26(2):99-110. doi: 10.1016/j.tcm.2015.05.008. Epub 2015 May 30. Review.

PMID:
26119078
30.

Non-coding RNA in control of gene regulatory programs in cardiac development and disease.

Philippen LE, Dirkx E, da Costa-Martins PA, De Windt LJ.

J Mol Cell Cardiol. 2015 Dec;89(Pt A):51-8. doi: 10.1016/j.yjmcc.2015.03.014. Epub 2015 Mar 27. Review.

PMID:
25820097
31.

Lack of UCP3 does not affect skeletal muscle mitochondrial function under lipid-challenged conditions, but leads to sudden cardiac death.

Nabben M, van Bree BWJ, Lenaers E, Hoeks J, Hesselink MKC, Schaart G, Gijbels MJJ, Glatz JFC, da Silva GJJ, de Windt LJ, Tian R, Mike E, Skapura DG, Wehrens XHT, Schrauwen P.

Basic Res Cardiol. 2014;109(6):447. doi: 10.1007/s00395-014-0447-4. Epub 2014 Oct 25.

32.

Nuclear calcium transients: Hermes Propylaios in the heart.

da Costa Martins PA, Leptidis S, De Windt LJ.

Circulation. 2014 Jul 15;130(3):221-3. doi: 10.1161/CIRCULATIONAHA.114.010675. Epub 2014 Jun 13. No abstract available.

PMID:
24928679
33.

Supplementing exposure to hypoxia with a copper depleted diet does not exacerbate right ventricular remodeling in mice.

Poels EM, Bitsch N, Slenter JM, Kooi ME, de Theije CC, de Windt LJ, van Empel VP, da Costa Martins PA.

PLoS One. 2014 Apr 15;9(4):e92983. doi: 10.1371/journal.pone.0092983. eCollection 2014.

34.

ESC Working Group on Myocardial Function Position Paper: how to study the right ventricle in experimental models.

Leite-Moreira AF, Lourenço AP, Balligand JL, Bauersachs J, Clerk A, De Windt LJ, Heymans S, Hilfiker-Kleiner D, Hirsch E, Iaccarino G, Kaminski KA, Knöll R, Mayr M, Tarone G, Thum T, Tocchetti CG.

Eur J Heart Fail. 2014 May;16(5):509-18. doi: 10.1002/ejhf.66. Epub 2014 Feb 23. Review.

35.

Towards modern genetics, diagnostics and therapeutics of heart failure in a new era.

De Windt LJ, Doevendans PA.

Biochim Biophys Acta. 2013 Dec;1832(12):2401-2. doi: 10.1016/j.bbadis.2013.10.010. No abstract available.

36.

miR-223: sailing to terra incognita for microRNAs in platelets.

Halkein J, De Windt LJ.

Thromb Haemost. 2013 Dec;110(6):1112-3. doi: 10.1160/TH13-10-0882. Epub 2013 Nov 7. No abstract available.

PMID:
24196692
37.

Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure.

Dirkx E, Gladka MM, Philippen LE, Armand AS, Kinet V, Leptidis S, El Azzouzi H, Salic K, Bourajjaj M, da Silva GJ, Olieslagers S, van der Nagel R, de Weger R, Bitsch N, Kisters N, Seyen S, Morikawa Y, Chanoine C, Heymans S, Volders PG, Thum T, Dimmeler S, Cserjesi P, Eschenhagen T, da Costa Martins PA, De Windt LJ.

Nat Cell Biol. 2013 Nov;15(11):1282-93. doi: 10.1038/ncb2866. Epub 2013 Oct 27.

PMID:
24161931
38.

Regulation of fetal gene expression in heart failure.

Dirkx E, da Costa Martins PA, De Windt LJ.

Biochim Biophys Acta. 2013 Dec;1832(12):2414-24. doi: 10.1016/j.bbadis.2013.07.023. Epub 2013 Sep 10. Review.

39.

The hypoxia-inducible microRNA cluster miR-199a∼214 targets myocardial PPARδ and impairs mitochondrial fatty acid oxidation.

el Azzouzi H, Leptidis S, Dirkx E, Hoeks J, van Bree B, Brand K, McClellan EA, Poels E, Sluimer JC, van den Hoogenhof MM, Armand AS, Yin X, Langley S, Bourajjaj M, Olieslagers S, Krishnan J, Vooijs M, Kurihara H, Stubbs A, Pinto YM, Krek W, Mayr M, da Costa Martins PA, Schrauwen P, De Windt LJ.

Cell Metab. 2013 Sep 3;18(3):341-54. doi: 10.1016/j.cmet.2013.08.009.

40.

Macrophage microRNA-155 promotes cardiac hypertrophy and failure.

Heymans S, Corsten MF, Verhesen W, Carai P, van Leeuwen RE, Custers K, Peters T, Hazebroek M, Stöger L, Wijnands E, Janssen BJ, Creemers EE, Pinto YM, Grimm D, Schürmann N, Vigorito E, Thum T, Stassen F, Yin X, Mayr M, de Windt LJ, Lutgens E, Wouters K, de Winther MP, Zacchigna S, Giacca M, van Bilsen M, Papageorgiou AP, Schroen B.

Circulation. 2013 Sep 24;128(13):1420-32. doi: 10.1161/CIRCULATIONAHA.112.001357. Epub 2013 Aug 16.

PMID:
23956210
41.

A deep sequencing approach to uncover the miRNOME in the human heart.

Leptidis S, El Azzouzi H, Lok SI, de Weger R, Olieslagers S, Kisters N, Silva GJ, Heymans S, Cuppen E, Berezikov E, De Windt LJ, da Costa Martins P.

PLoS One. 2013;8(2):e57800. doi: 10.1371/journal.pone.0057800. Epub 2013 Feb 27. Erratum in: PLoS One. 2013;8(6). doi:10.1371/annotation/e33f9763-3385-42c7-b31e-d433dc8e499a. Olieslagers, Serv [corrected to Olieslagers, Servé].

42.

An SRF/miR-1 axis regulates NCX1 and annexin A5 protein levels in the normal and failing heart.

Tritsch E, Mallat Y, Lefebvre F, Diguet N, Escoubet B, Blanc J, De Windt LJ, Catalucci D, Vandecasteele G, Li Z, Mericskay M.

Cardiovasc Res. 2013 Jun 1;98(3):372-80. doi: 10.1093/cvr/cvt042. Epub 2013 Feb 22.

PMID:
23436819
43.

Circulating miRNAs: reflecting or affecting cardiovascular disease?

van Empel VP, De Windt LJ, da Costa Martins PA.

Curr Hypertens Rep. 2012 Dec;14(6):498-509. doi: 10.1007/s11906-012-0310-7. Review.

PMID:
22996205
44.

Targeting microRNA targets.

Da Costa Martins PA, De Windt LJ.

Circ Res. 2012 Aug 17;111(5):506-8. doi: 10.1161/CIRCRESAHA.112.276717. No abstract available.

PMID:
22904037
45.

Relevance of calmodulin/CaMKII activation for arrhythmogenesis in the AV block dog.

Bourgonje VJ, Schoenmakers M, Beekman JD, van der Nagel R, Houtman MJ, Miedema LF, Antoons G, Sipido K, de Windt LJ, van Veen TA, Vos MA.

Heart Rhythm. 2012 Nov;9(11):1875-83. doi: 10.1016/j.hrthm.2012.07.023. Epub 2012 Jul 27.

PMID:
22846339
46.

MEK1 inhibits cardiac PPARα activity by direct interaction and prevents its nuclear localization.

el Azzouzi H, Leptidis S, Bourajjaj M, van Bilsen M, da Costa Martins PA, De Windt LJ.

PLoS One. 2012;7(6):e36799. doi: 10.1371/journal.pone.0036799. Epub 2012 Jun 19.

47.

MicroRNAs as biomarkers for myocardial infarction.

Salic K, De Windt LJ.

Curr Atheroscler Rep. 2012 Jun;14(3):193-200. doi: 10.1007/s11883-012-0238-z. Review.

48.

MicroRNAs in control of cardiac hypertrophy.

Da Costa Martins PA, De Windt LJ.

Cardiovasc Res. 2012 Mar 15;93(4):563-72. doi: 10.1093/cvr/cvs013. Epub 2012 Jan 19. Review.

PMID:
22266752
49.

Dominant-negative control of cAMP-dependent IKs upregulation in human long-QT syndrome type 1.

Heijman J, Spätjens RL, Seyen SR, Lentink V, Kuijpers HJ, Boulet IR, de Windt LJ, David M, Volders PG.

Circ Res. 2012 Jan 20;110(2):211-9. doi: 10.1161/CIRCRESAHA.111.249482. Epub 2011 Nov 17.

PMID:
22095730
50.

Apoptosis-inducing factor regulates skeletal muscle progenitor cell number and muscle phenotype.

Armand AS, Laziz I, Djeghloul D, Lécolle S, Bertrand AT, Biondi O, De Windt LJ, Chanoine C.

PLoS One. 2011;6(11):e27283. doi: 10.1371/journal.pone.0027283. Epub 2011 Nov 4.

Supplemental Content

Loading ...
Support Center